Home > Boards > US Listed > Biotechs > Regeneron Pharmaceuticals (REGN)

EPS = 11.27

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
TREND1 Member Profile
Member Level 
Followed By 402
Posts 52,623
Boards Moderated 24
Alias Born 12/16/01
160x600 placeholder
Regeneron Announces the 2019 Winners of the Regeneron Prize for Creative Innovation PR Newswire (US) - 7/18/2019 7:30:00 AM
Drugmakers Rise After Trump Pricing Rule Is Blocked Dow Jones News - 7/9/2019 5:37:00 PM
Drugmakers Rise After Trump Pricing Rule Is Blocked Dow Jones News - 7/9/2019 1:58:00 PM
Regeneron to Report Second Quarter 2019 Financial and Operating Results and Host Conference Call and Webcast on August 6, 201... PR Newswire (US) - 7/8/2019 9:30:00 AM
Libtayo® (cemiplimab) Approved for Advanced Cutaneous Squamous Cell Carcinoma in the European Union PR Newswire (US) - 7/1/2019 10:00:00 AM
Committee Recommends Approval for Dermatitis Treatment Be Extended Dow Jones News - 6/28/2019 8:03:00 AM
CHMP Recommends Approval of Dupixent® (dupilumab) for Moderate-to-Severe Atopic Dermatitis in Adolescents PR Newswire (US) - 6/28/2019 6:59:00 AM
FDA Approves Sanofi, Regeneron Treatment for Chronic Rhinosinusitis with Nasal Polyposis Dow Jones News - 6/26/2019 2:30:00 PM
FDA approves Dupixent® (dupilumab) for chronic rhinosinusitis with nasal polyposis PR Newswire (US) - 6/26/2019 1:30:00 PM
FDA Approves Dupixent® (dupilumab) for Chronic Rhinosinusitis with Nasal Polyposis PR Newswire (US) - 6/26/2019 1:29:00 PM
Regeneron, Sanofi Report Positive Topline Phase 2 Asthma Results Dow Jones News - 6/21/2019 6:39:00 AM
Regeneron and Sanofi Announce Positive Topline Phase 2 Results for IL-33 Antibody in Asthma PR Newswire (US) - 6/21/2019 12:59:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/19/2019 5:21:45 PM
Regeneron Says Early-Stage Results Positive for REGN1979 in Lymphoma Dow Jones News - 6/14/2019 7:56:00 AM
Regeneron CD20xCD3 Bispecific REGN1979 Shows Positive Results in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymp... PR Newswire (US) - 6/14/2019 7:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/29/2019 4:19:22 PM
Regeneron Announces Upcoming Investor Conference Presentation PR Newswire (US) - 5/23/2019 9:30:00 AM
Updated Libtayo® (cemiplimab-rwlc) Results Reinforce Durable and Substantial Response Rates in Advanced Cutaneous Squamous C... PR Newswire (US) - 5/16/2019 7:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/15/2019 4:05:42 PM
Confidential Treatment Order (ct Order) Edgar (US Regulatory) - 5/14/2019 10:47:54 AM
FDA Approves EYLEA® (aflibercept) Injection for Diabetic Retinopathy PR Newswire (US) - 5/13/2019 4:19:00 PM
Regeneron Says FDA Approves Eylea Injection for All Diabetic Retinopathy Treatment Dow Jones News - 5/13/2019 3:29:00 PM
FDA Approves EYLEA® (aflibercept) Injection for Diabetic Retinopathy PR Newswire (US) - 5/13/2019 2:45:00 PM
Confidential Treatment Order (ct Order) Edgar (US Regulatory) - 5/9/2019 4:52:51 PM
Amended Current Report Filing (8-k/a) Edgar (US Regulatory) - 5/7/2019 5:01:44 PM
TREND1 Member Level  Monday, 09/24/18 07:36:18 PM
Re: None
Post # of 135 
EPS = 11.27

All my posts are just my opinions. I receive no compensation for
posts. These posts are for entertainment purposes only. I maybe
long or short or hold no position.
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist